Bronchopulmonary Dysplasia: An Update of Current Pharmacologic Therapies and New Approaches

DOI Web Site Web Site 2 Citations
  • Zoe Michael
    Department of Pediatric Newborn Medicine, Brigham and Women’s Hospital, Boston, MA, USA
  • Fotios Spyropoulos
    Department of Pediatric Newborn Medicine, Brigham and Women’s Hospital, Boston, MA, USA
  • Sailaja Ghanta
    Department of Pediatric Newborn Medicine, Brigham and Women’s Hospital, Boston, MA, USA
  • Helen Christou
    Department of Pediatric Newborn Medicine, Brigham and Women’s Hospital, Boston, MA, USA

Search this article

Description

<jats:p> Bronchopulmonary dysplasia (BPD) remains the most prevalent long-term morbidity of surviving extremely preterm infants and is associated with significant health care utilization in infancy and beyond. Recent advances in neonatal care have resulted in improved survival of extremely low birth weight (ELBW) infants; however, the incidence of BPD has not been substantially impacted by novel interventions in this vulnerable population. The multifactorial cause of BPD requires a multi-pronged approach for prevention and treatment. New approaches in assisted ventilation, optimal nutrition, and pharmacologic interventions are currently being evaluated. The focus of this review is the current state of the evidence for pharmacotherapy in BPD. Promising future approaches in need of further study will also be reviewed. </jats:p>

Journal

Citations (2)*help

See more

Report a problem

Back to top